ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FDA stiff-arms Regeneron's bid for more convenient—and competitive—Eylea dosing
August 14, 2018Regeneron, which was thinking its blockbuster eye drug Eylea would extend its market dominance with a new, more convenient 12-week dosing schedule for some patients, is having to think twice. The FDA has interrupted those plans with delivery of a CRL.
Pharma Sources Insight January 2025
